CPP-109 is Catalyst's tablet formulation of vigabatrin being developed as a treatment for cocaine and methamphetamine addiction, as well as other addictions and obsessive-compulsive disorders. The randomized, double-blind, placebo-controlled clinical trial is assessing safety and efficacy of CPP-109 over a 12 week treatment period, with an additional 12 weeks of follow-up. The specified total of 180 patients have now been enrolled at 11 addiction research facilities across the US. Catalyst expects to have top-line results from the trial during the second quarter of 2009. Douglas Winship, vice president of regulatory operations at Catalyst, said: "We look forward with great anticipation to the results of this cocaine dependency trial and the opportunity to improve treatment outcomes of such patients everywhere." http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon For full details for CPRX click here.
![]()
Email Print Archives Feedback Email Article Link
Close X
Most Popular News
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
|